JACC. Cardiovascular interventions · 2025
Long-Term Outcomes in Moderate and Severe Aortic Stenosis According to Extent of Cardiac Damage.
СтатьяСравнительное исследованиеНаблюдательное исследованиеПоддержка исследования: вне правительства СШАНазвание и аннотация: Перевод в очереди
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Angellotti Domenico, Ryffel Christoph, Schmid Lisa, Räber Lorenz, Heg Dik, Stortecky Stefan, Wild Mirjam, Lanz Jonas, Fürholz Monika, Siontis George C M, Praz Fabien, Tomii Daijiro, Brugger Nicolas, de Marchi Stefano, Häner Jonas, Samim Daryoush, Bartkowiak Joanna, Rohla Miklos, Hunziker Lukas, Corpataux Noé, Susuri Njomeza, Gebhard Catherine, Windecker Stephan, Pilgrim Thomas
Аннотация
BACKGROUND: Cardiac damage (CD) significantly affects the prognosis of patients with aortic stenosis (AS).
OBJECTIVES: The aim of this study was to investigate the impact of CD on long-term survival in patients with moderate and severe AS.
METHODS: In a pooled analysis of 2 single-center registries, patients with moderate or severe AS were included according to the presence of early (stages 0 and 1) or advanced (stages 2-4) CD.
RESULTS: Among 1,096 patients with AS included between 2009 and 2023, 626 patients (mean age 78.9 ± 8.0 years, 33.1% women) had moderate (n = 343) or severe AS (n = 283). Advanced CD was present in 497 patients (79.4%), and the median follow-up duration was 7.4 years (Q1-Q3: 4.2-10.6 years). There was a gradual increase in the risk for 10-year mortality from moderate to severe AS and from early CD (moderate AS: reference; severe AS: adjusted HR [aHR]: 1.42; 95% CI: 0.75-2.72) to advanced CD (moderate AS: aHR: 1.91; 95% CI: 1.22-2.97; severe AS: aHR: 2.77; 95% CI: 1.73-4.45). At a median 347 days, 344 patients (54.9%) had undergone aortic valve replacement (AVR). In patients with advanced CD, AVR was associated with lower mortality compared with conservative management, irrespective of AS severity (moderate AS: aHR: 0.43; 95% CI: 0.28-0.66; severe AS: aHR: 0.27; 95% CI: 0.18-0.39). In patients with early CD, AVR was associated with lower mortality in patients with severe AS (aHR: 0.29; 95% CI: 0.10-0.86), but not in those with moderate AS (aHR: 0.61; 95% CI: 0.25-1.44).
CONCLUSIONS: Ten-year mortality in patients with moderate and severe AS is importantly determined by CD extent. AVR was associated with lower mortality in patients with moderate AS and advanced CD.
OBJECTIVES: The aim of this study was to investigate the impact of CD on long-term survival in patients with moderate and severe AS.
METHODS: In a pooled analysis of 2 single-center registries, patients with moderate or severe AS were included according to the presence of early (stages 0 and 1) or advanced (stages 2-4) CD.
RESULTS: Among 1,096 patients with AS included between 2009 and 2023, 626 patients (mean age 78.9 ± 8.0 years, 33.1% women) had moderate (n = 343) or severe AS (n = 283). Advanced CD was present in 497 patients (79.4%), and the median follow-up duration was 7.4 years (Q1-Q3: 4.2-10.6 years). There was a gradual increase in the risk for 10-year mortality from moderate to severe AS and from early CD (moderate AS: reference; severe AS: adjusted HR [aHR]: 1.42; 95% CI: 0.75-2.72) to advanced CD (moderate AS: aHR: 1.91; 95% CI: 1.22-2.97; severe AS: aHR: 2.77; 95% CI: 1.73-4.45). At a median 347 days, 344 patients (54.9%) had undergone aortic valve replacement (AVR). In patients with advanced CD, AVR was associated with lower mortality compared with conservative management, irrespective of AS severity (moderate AS: aHR: 0.43; 95% CI: 0.28-0.66; severe AS: aHR: 0.27; 95% CI: 0.18-0.39). In patients with early CD, AVR was associated with lower mortality in patients with severe AS (aHR: 0.29; 95% CI: 0.10-0.86), but not in those with moderate AS (aHR: 0.61; 95% CI: 0.25-1.44).
CONCLUSIONS: Ten-year mortality in patients with moderate and severe AS is importantly determined by CD extent. AVR was associated with lower mortality in patients with moderate AS and advanced CD.